Endometriosis
Showing NaN - NaN of 12
Endometriosis Trial in Worldwide (Relugolix, Estradiol/norethindrone acetate)
Active, not recruiting
- Endometriosis
- Relugolix
- Estradiol/norethindrone acetate
-
Andalusia, Alabama
- +168 more
May 31, 2022
Endometriosis Trial in United States (Leuprolide Oral Tablet - 120 mg - QD- Treatment A, Leuprolide Oral Tablet - 80 mg - QD -
Recruiting
- Endometriosis
- Leuprolide Oral Tablet - 120 mg - QD- Treatment A
- +4 more
-
Sarasota, Florida
- +3 more
Mar 21, 2022
Endometriosis Trial in Canada, Puerto Rico, United States (Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix)
Active, not recruiting
- Endometriosis
- Estradiol/Norethindrone Acetate
- +3 more
-
Birmingham, Alabama
- +196 more
Feb 14, 2022
The EMPOWER Study: Endometriosis Diagnosis Using microRNA
Recruiting
- Endometriosis
-
Palo Alto, California
- +22 more
Jan 11, 2022
Women Receiving Standard of Care for Treatment of Pelvic Pain
Terminated
- Endometriosis
- +2 more
-
Birmingham, Alabama
- +116 more
Nov 16, 2021
Endometriosis Trial in United States (elagolix, estradiol/norethindrone acetate (E2/NETA))
Terminated
- Endometriosis
- elagolix
- estradiol/norethindrone acetate (E2/NETA)
-
Anniston, Alabama
- +36 more
Nov 8, 2019
Validation Study for Endometriosis PRO
Completed
- Endometriosis
- No drug
-
Jonesboro, Arkansas
- +20 more
Oct 10, 2014